Clinical Trial

Long-Term Safety and Efficacy of HSK39004 Dry Powder Inhaler in COPD

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This clinical trial evaluates the long-term safety and efficacy of 0.75 mg HSK39004 Dry Powder Inhaler administered twice daily for 52 weeks in subjects aged 40 to 80 years with moderate-to-severe stable chronic obstructive pulmonary disease (COPD), including both newly enrolled and those who have completed prior participation in the HSK39004-201, HSK39004-T1-201, or HSK39004-T1-202 studies as a long-term extension.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-13.
Trial Details
NCT Number NCT07425210
Lead Sponsor Haisco Pharmaceutical Group Co., Ltd.
Conditions Chronic Obstructive Lung Disease (COLD)
Enrollment 300 participants
Start Date 2026-03
Primary Completion 2027-07 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-02-25